Dr. Treon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Avenue
Boston, MA 02215Phone+1 617-632-2681Fax+1 617-632-4862- Is this information wrong?
Summary
- Dr. Steven Treon is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, and North Shore Medical Center. He received his medical degree from Boston University School of Medicine and has been in practice 24 years. He specializes in hematologic oncology and is experienced in hematologic oncology and waldenstrom macroglobulinemia.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1997
- Boston University Medical CenterResidency, Internal Medicine, 1992 - 1995
- Boston University School of MedicineClass of 1993
Certifications & Licensure
- MA State Medical License 1994 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Start of enrollment: 2003 May 01
- Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia Start of enrollment: 2003 Dec 01
- Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 2002 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.Lantermans, H., Ma, F., Kuil, A., van Kesteren, S., Yasinoglu, S., Yang, G., Buhrlage, S., Wang, J., Gray, N., Kersten, M., Pals, S., Spaargaren, M., Treon, S.> ;Leukemia. 2024 Mar 7
- 1 citationsIbrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.Castillo, J., Branagan, A., Sermer, D., Flynn, C., Meid, K., Little, M., Stockman, K., White, T., Canning, A., Guerrera, M., Kofides, A., Liu, S., Liu, X., Richardson,...> ;Blood. 2024 Feb 15
- Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia.Tam, C., Opat, S., D'Sa, S., Jurczak, W., Lee, H., Cull, G., Owen, R., Marlton, P., Wahlin, B., Garcia-Sanz, R., McCarthy, H., Mulligan, S., Tedeschi, A., Castillo, J....> ;Blood Advances. 2024 Feb 5
- Join now to see all
Journal Articles
- Bortezomib Overcomes the Negative Impact of CXCR4 Mutations on Survival of Waldenstrom's Macroglobulinemia PatientsKaitlen Reyes, Steven P Treon, Irene M Ghobrial, Blood
- TP53 Mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström MacroglobulinaemiaToni Dubeau, Steven P Treon, Jorge J Castillo, Christopher J Patterson, British Journal of Haematology
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s MacroglobulinemiaJeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine
Abstracts/Posters
- CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome InhibitorsSteven P Treon, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
- A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 M...Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstr_m Macroglobulinemia Treated with IbrutinibSteven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MY...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- FDA Greenlights BeiGene’s Brukinsa for Waldenstrom’s MacroglobulinemiaSeptember 2nd, 2021
- U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s MacroglobulinemiaSeptember 1st, 2021
- BTK Blockers Make Headway in Multiple SclerosisJanuary 11th, 2021
- Join now to see all
Grant Support
- Novel Serotherapy Strategies--Plasma Cell MalignanciesNational Cancer Institute2000–2004
Professional Memberships
- Member
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
- North Shore Medical CenterSalem, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: